Free Trial

Calumet (NASDAQ:CLMT) Stock Crosses Above 200 Day Moving Average - Time to Sell?

Calumet logo with Energy background

Calumet, Inc. (NASDAQ:CLMT - Get Free Report)'s stock price passed above its 200-day moving average during trading on Wednesday . The stock has a 200-day moving average of $14.83 and traded as high as $16.82. Calumet shares last traded at $16.34, with a volume of 1,282,363 shares traded.

Wall Street Analyst Weigh In

A number of research firms have recently weighed in on CLMT. Wells Fargo & Company reduced their target price on shares of Calumet from $23.00 to $21.00 and set an "overweight" rating on the stock in a research report on Wednesday, May 14th. Bank of America began coverage on shares of Calumet in a research report on Tuesday, May 13th. They set a "buy" rating and a $15.00 price objective on the stock. The Goldman Sachs Group cut their price objective on shares of Calumet from $16.00 to $14.00 and set a "buy" rating on the stock in a research report on Wednesday, April 30th. Finally, UBS Group raised shares of Calumet from a "sell" rating to a "neutral" rating and cut their price objective for the company from $15.00 to $12.00 in a research report on Monday, March 17th. One equities research analyst has rated the stock with a sell rating, two have given a hold rating and four have assigned a buy rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of "Hold" and an average price target of $18.50.

Check Out Our Latest Research Report on Calumet

Calumet Trading Up 2.2%

The firm has a market cap of $1.44 billion, a P/E ratio of -4.18 and a beta of 0.93. The company's 50 day simple moving average is $14.02 and its 200-day simple moving average is $14.73.

Calumet (NASDAQ:CLMT - Get Free Report) last posted its earnings results on Friday, May 9th. The oil and gas company reported ($1.03) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.41) by ($0.62). The business had revenue of $993.90 million for the quarter, compared to analyst estimates of $899.62 million. The business's revenue for the quarter was down 1.2% on a year-over-year basis. During the same quarter in the prior year, the company earned ($0.51) EPS. On average, sell-side analysts anticipate that Calumet, Inc. will post -3.02 earnings per share for the current year.

Insider Buying and Selling at Calumet

In other Calumet news, SVP Gregory J. Morical sold 25,123 shares of the company's stock in a transaction dated Monday, June 16th. The shares were sold at an average price of $16.69, for a total transaction of $419,302.87. Following the transaction, the senior vice president owned 39,415 shares in the company, valued at approximately $657,836.35. This represents a 38.93% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Stephen P. Mawer sold 3,655 shares of the stock in a transaction that occurred on Tuesday, April 22nd. The stock was sold at an average price of $9.29, for a total transaction of $33,954.95. Following the completion of the transaction, the director owned 283,652 shares in the company, valued at $2,635,127.08. This trade represents a 1.27% decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 278,778 shares of company stock worth $4,147,258. Company insiders own 4.07% of the company's stock.

Hedge Funds Weigh In On Calumet

A hedge fund recently raised its stake in Calumet stock. Goldman Sachs Group Inc. lifted its holdings in Calumet, Inc. (NASDAQ:CLMT - Free Report) by 33.5% during the 1st quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 465,269 shares of the oil and gas company's stock after purchasing an additional 116,777 shares during the period. Goldman Sachs Group Inc. owned about 0.54% of Calumet worth $5,900,000 at the end of the most recent reporting period. Institutional investors own 34.41% of the company's stock.

About Calumet

(Get Free Report)

Calumet, Inc engages in the manufacturing, formulating, and marketing of a diversified slate of specialty branded products and renewable fuels to customers across a broad range of consumer-facing and industrial markets. It operates through the following segments: Specialty Products & Solutions, Performance Brands, Montana/Renewables, and Corporate.

Featured Articles

Should You Invest $1,000 in Calumet Right Now?

Before you consider Calumet, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Calumet wasn't on the list.

While Calumet currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

Analysts Agree—These Gold Picks Outshine the Rest Cover

Unlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

ACT FAST! Congress is Dumping these 3 Stocks
3 “Boring” Mega Cap Stocks to Turn Into Pure Profit
Joby vs. Archer: The $10 Billion eVTOL Battle

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines